Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2015 1
2021 1
2023 1
2024 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4 results

Results by year

Filters applied: . Clear all
Page 1
Genome-wide epistasis study highlights genetic interactions influencing severity of COVID-19.
Lin S, Gao X, Degenhardt F, Qian Y, Liu T, Ramon XF, Hadi SS, Romero-Gómez M, Fernández J, Albillos A, Ferret MB, Bujanda L, Julià A, de Cid R, Asselta R, Franke A, Liu F. Lin S, et al. Among authors: ferret mb. Eur J Epidemiol. 2023 Aug;38(8):883-889. doi: 10.1007/s10654-023-01020-5. Epub 2023 Jun 26. Eur J Epidemiol. 2023. PMID: 37358671
COVID-19 and digestive health: Implications for prevention, care and the use of COVID-19 vaccines in vulnerable patients.
Peck-Radosavljevic M, Burra P, Ferret MB, Fracasso P, Ricciardiello L, Seufferlein T, Van Hootegem P, van Leerdam M, Zelber-Sagi S; UEG Public Affairs Committee. Peck-Radosavljevic M, et al. Among authors: ferret mb. United European Gastroenterol J. 2021 Nov;9(9):1091-1095. doi: 10.1002/ueg2.12173. Epub 2021 Oct 30. United European Gastroenterol J. 2021. PMID: 34716760 Free PMC article. No abstract available.
Randomised clinical trial: alisporivir combined with peginterferon and ribavirin in treatment-naïve patients with chronic HCV genotype 1 infection (ESSENTIAL II).
Zeuzem S, Flisiak R, Vierling JM, Mazur W, Mazzella G, Thongsawat S, Abdurakhmanov D, Van Kính N, Calistru P, Heo J, Stanciu C, Gould M, Makara M, Hsu SJ, Buggisch P, Samuel D, Mutimer D, Nault B, Merz M, Bao W, Griffel LH, Brass C, Naoumov NV; ESSENTIAL II Study Group. Zeuzem S, et al. Aliment Pharmacol Ther. 2015 Oct;42(7):829-44. doi: 10.1111/apt.13342. Epub 2015 Aug 4. Aliment Pharmacol Ther. 2015. PMID: 26238707 Clinical Trial.
Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B.
Hou J, Zhang W, Xie Q, Hua R, Tang H, Morano Amado LE, Yang SS, Peng CY, Su WW, Chuang WL, Kim DJ, Avihingsanon A, Kao JH, Leerapun A, Yuen MF, Asselah T, Liang X, Bo Q, Canducci F, Catanese MT, Chen E, Cheng C, Chughlay F, Das S, Glavini K, Guerreiro N, Huang Y, Kakrana P, Kazma R, Patil A, Pavlovic V, Surujbally B, Triyatni M, Upmanyu R, Wat C, Gane E; Piranga Study Group. Hou J, et al. N Engl J Med. 2024 Dec 5;391(22):2098-2109. doi: 10.1056/NEJMoa2405485. N Engl J Med. 2024. PMID: 39774313 Clinical Trial.